Author:
Huang Shih-ying,Bolch Wesley E.,Lee Choonsik,Van Brocklin Henry F.,Pampaloni Miguel H.,Hawkins Randall A.,Sznewajs Aimee,DuBois Steven G.,Matthay Katherine K.,Seo Youngho
Publisher
Springer Science and Business Media LLC
Subject
Cancer Research,Radiology Nuclear Medicine and imaging,Oncology
Reference36 articles.
1. Matthay KK, Tan JC, Villablanca JG et al (2006) Phase I dose escalation of iodine-131-metaiodobenzylguanidine with myeloablative chemotherapy and autologous stem-cell transplantation in refractory neuroblastoma: a new approaches to Neuroblastoma Therapy Consortium Study. J Clin Oncol 24:500–6
2. Matthay KK, Weiss B, Villablanca JG et al (2012) Dose escalation study of no-carrier-added 131I-metaiodobenzylguanidine for relapsed or refractory neuroblastoma: new approaches to neuroblastoma therapy consortium trial. J Nucl Med 53:1155–63
3. Matthay KK, Yanik G, Messina J et al (2007) Phase II study on the effect of disease sites, age, and prior therapy on response to iodine-131-metaiodobenzylguanidine therapy in refractory neuroblastoma. J Clin Oncol 25:1054–60
4. Carlin S, Mairs RJ, McCluskey AG et al (2003) Development of a real-time polymerase chain reaction assay for prediction of the uptake of meta-[(131)I]iodobenzylguanidine by neuroblastoma tumors. Clin Cancer Res 9:3338–44
5. Treuner J, Feine U, Niethammer D et al (1984) Scintigraphic imaging of neuroblastoma with [131-I]iodobenzylguanidine. Lancet 1:333–4
Cited by
66 articles.
订阅此论文施引文献
订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献